JSKN021 is a “2-in-1” dual payload bispecific ADC targeting EGFR and HER3. By leveraging glycan-specific conjugation technology, it precisely and quantitatively links two different cytotoxic payloads ...

Co-occurring alterations in EGFR-mutant NSCLC are increasingly detected via broad NGS and may signal aggressive biology, prompting interest in escalation strategies that address concurrent drivers.

Barclays 28th Annual Global Healthcare Conference March 10, 2026 11:30 AM EDTCompany ParticipantsRyan Cohlhepp - ...

Net Loss: Net loss attributable to Cullinan was $50.7 million for the fourth quarter of 2025, compared to $47.6 million for the same period in 2024, and $219.9 million for the full year 2025, compared ...

Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond progression.

BUFFALO, N.Y. — For decades, pharmacists and medical institutions have relied on the Cockcroft-Gault (C-G) estimated creatinine clearance assessment to determine medication dosing and treatment for ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 2:30 PM ESTCompany ParticipantsDave Gancarz - Chief Business ...

EGFR-positive lung cancer is more common in non-smokers (particularly those with adenocarcinoma) and younger adults, as it often develops from a single genetic mutation rather than widespread DNA ...

For many people with IgA nephropathy (IgAN), a condition in which immunoglobulin A (IgA) antibodies accumulate in the kidneys and trigger inflammation, kidney function stays stable for many years. For ...

Dr. Girindra Raval sat down for an interview with CURE to discuss what patients with EGFR-mutated lung cancer should know about their treatment options. Dr. Girindra Raval sat down for an interview ...

Having a cystatin C-based eGFR value at least 30% lower than creatinine-based eGFR is associated with increased risks of early death, cardiovascular events, and kidney failure requiring replacement ...